GlassScriptPhysician profile
David Richard Kafonek
NPI 1609834894
$3,300.23
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,875 · 2020: $871 · 2021: $542 · 2022: $12.73.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,122.27 | 2019-2021 | |
| Janssen Biotech, INC. | $531.24 | 2019-2022 | |
| Daiichi Sankyo INC. | $412.19 | 2019-2021 | |
| Qol Medical, LLC | $266.54 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $213.82 | 2019-2021 | |
| Pfizer INC. | $193.48 | 2019-2020 | |
| Braintree Laboratories, INC. | $164.25 | 2021 | |
| Allergan, INC. | $142.72 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.11 | 2019-2020 | |
| Ucb, INC. | $39.21 | 2019 | |
| Ferring Pharmaceuticals INC. | $24.48 | 2020 | |
| Ironwood Pharmaceuticals, INC | $17.39 | 2020 | |
| Alfasigma USA, INC. | $15.34 | 2020 | |
| Celgene Corporation | $12.57 | 2021 | |
| Foundation Medicine, INC. | $11.62 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kafonek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.